BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 35900732)

  • 1. Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration.
    Modi ND; Abuhelwa AY; McKinnon RA; Boddy AV; Haseloff M; Wiese MD; Hoffmann TC; Perakslis ED; Rowland A; Sorich MJ; Hopkins AM
    JAMA Oncol; 2022 Sep; 8(9):1310-1316. PubMed ID: 35900732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity and Utility of Pharmaceutical Company Sharing of Individual-Participant Data Packages.
    Hopkins AM; Modi ND; Abuhelwa AY; Kichenadasse G; Kuderer NM; Lyman GH; Wiese MD; McKinnon RA; Rockhold FW; Mann A; Rowland A; Sorich MJ
    JAMA Oncol; 2023 Dec; 9(12):1621-1626. PubMed ID: 37796495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accessibility of clinical study reports supporting medicine approvals: a cross-sectional evaluation.
    Hopkins AM; Modi ND; Rockhold FW; Hoffmann T; Menz BD; Veroniki AA; McKinnon RA; Rowland A; Swain SM; Ross JS; Sorich MJ
    J Clin Epidemiol; 2024 Mar; 167():111263. PubMed ID: 38219810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices.
    Miller J; Ross JS; Wilenzick M; Mello MM
    BMJ; 2019 Jul; 366():l4217. PubMed ID: 31292127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Data sharing from pharmaceutical industry sponsored clinical studies: audit of data availability.
    Hopkins AM; Rowland A; Sorich MJ
    BMC Med; 2018 Sep; 16(1):165. PubMed ID: 30261889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial transparency and data sharing among biopharmaceutical companies and the role of company size, location and product type: a cross-sectional descriptive analysis.
    Axson S; Mello MM; Lincow D; Yang C; Gross C; Ross JS; Miller J
    BMJ Open; 2021 Jul; 11(7):e053248. PubMed ID: 34281933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Availability of Clinical Trial Data From Industry-Sponsored Cardiovascular Trials.
    Murugiah K; Ritchie JD; Desai NR; Ross JS; Krumholz HM
    J Am Heart Assoc; 2016 Apr; 5(4):e003307. PubMed ID: 27098969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.
    Skydel JJ; Luxkaranayagam AT; Dhruva SS; Ross JS; Wallach JD
    JAMA Netw Open; 2019 May; 2(5):e193410. PubMed ID: 31074812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
    Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
    BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
    Puthumana J; Miller JE; Kim J; Ross JS
    JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
    Lythgoe MP; Desai A; Gyawali B; Savage P; Krell J; Warner JL; Khaki AR
    JAMA Netw Open; 2022 Jun; 5(6):e2216183. PubMed ID: 35687337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.
    Downing NS; Aminawung JA; Shah ND; Krumholz HM; Ross JS
    JAMA; 2014 Jan 22-29; 311(4):368-77. PubMed ID: 24449315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration.
    Hutchinson N; Carlisle B; Doussau A; Bosan R; Gumnit E; MacPherson A; Fergusson DA; Kimmelman J
    JAMA Netw Open; 2021 May; 4(5):e2110456. PubMed ID: 34003270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs.
    Miller JE; Mello MM; Wallach JD; Gudbranson EM; Bohlig B; Ross JS; Gross CP; Bach PB
    JAMA Netw Open; 2021 May; 4(5):e217075. PubMed ID: 33950209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obtaining and managing data sets for individual participant data meta-analysis: scoping review and practical guide.
    Ventresca M; Schünemann HJ; Macbeth F; Clarke M; Thabane L; Griffiths G; Noble S; Garcia D; Marcucci M; Iorio A; Zhou Q; Crowther M; Akl EA; Lyman GH; Gloy V; DiNisio M; Briel M
    BMC Med Res Methodol; 2020 May; 20(1):113. PubMed ID: 32398016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Data Sharing After Implementation of the International Committee of Medical Journal Editors Data Sharing Statement Requirement.
    Danchev V; Min Y; Borghi J; Baiocchi M; Ioannidis JPA
    JAMA Netw Open; 2021 Jan; 4(1):e2033972. PubMed ID: 33507256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study.
    Zeitoun JD; Baron G; Vivot A; Atal I; Downing NS; Ross JS; Ravaud P
    Int J Cancer; 2018 Jan; 142(2):414-423. PubMed ID: 28929484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review.
    Arciero V; Delos Santos S; Koshy L; Rahmadian A; Saluja R; Everest L; Parmar A; Chan KKW
    JAMA Netw Open; 2021 Feb; 4(2):e2033004. PubMed ID: 33570573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.